EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Comparison of the Diagnostic Performances of ACR-TIRADS, EU-TIRADS, and Bethesda Classifications in Predicting Malignancy in Thyroid Nodules

Mehmet Tonkaz, Esra Pınar, Gökhan Tonkaz, Duygu Erkal, Serdar Aslan, Tumay Bekci, Ilker Sengul, Iskender Aksoy, Demet Sengul

The European Research Journal · 2026-11-06 · 1-10

DOI: 10.18621/eurj.1425 ↗
AbstractBibliografische Angaben

Abstract

Objective: To compare the diagnostic performance of ultrasound-based risk stratification systems (ACR-TIRADS and EU-TIRADS) with the Bethesda classification in predicting thyroid nodule malignancy. Methods: This prospective cohort study included consecutive patients undergoing ultrasound-guided fine-needle aspiration biopsy between January 3 and December 30, 2024. Among 239 enrolled patients, 154 with histopathological confirmation following thyroidectomy were analyzed. Nodules were classified using ACR-TIRADS and EU-TIRADS criteria; cytological findings were categorized via the Bethesda system. Diagnostic performance was evaluated using receiver operating characteristic (ROC) curve analysis, and independent predictors of malignancy were identified through logistic regression. Results: Among 154 operated patients, histopathology confirmed malignancy in 40.3% of nodules. Malignancy rates increased significantly with advancing categories across all 3 systems (P < .001). Individual performances were moderate and statistically similar: ACR-TIRADS (area under the curve [AUC], 0.72), EU-TIRADS (AUC, 0.71), and Bethesda (AUC, 0.72) (ACR-TIRADS vs EU-TIRADS, DeLong test, P = .70). Accuracy improved when all systems were combined (AUC, 0.78). On multivariable analysis, only Bethesda remained an independent predictor of malignancy (odds ratio, 1.96; P < .001). In the cytologically indeterminate Bethesda III–IV subgroup (n = 73), both TIRADS systems demonstrated high sensitivity (85.2%) but low specificity (37.0% to 39.1%; AUC range, 0.65 to 0.68). Conclusion: Bethesda cytology was the strongest independent predictor of thyroid malignancy. ACR-TIRADS and EU-TIRADS provide valuable complementary roles in determining biopsy indications, particularly for cytologically indeterminate nodules. Combined assessment optimizes diagnostic accuracy and supports clinical decision-making.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →